Aptus Pharma Limited held a Board of Directors meeting on Friday, 12th June, 2026, from 4:00 p.m. to 5:30 p.m. at its corporate office in Rajkot, Gujarat. The meeting was conducted pursuant to Regulation 30 of the SEBI LODR Regulations.

Key Outcomes:

1. Approval of Fund Raising Proposal:

The Board approved an in-principle proposal to raise funds aggregating up to ₹51,00,00,000 (Rupees Fifty-One Crores) for expansion of business operations. The fund raising will be structured through three components:

  • Preferential Allotment of securities: Up to ₹35,00,00,000 (Rupees Thirty-Five Crores)
  • Debt Finance / Borrowings: Up to ₹10,00,00,000 (Rupees Ten Crores)
  • Internal Accruals: ₹6,00,00,000 (Rupees Six Crores)

The preferential allotment will be undertaken in accordance with the Companies Act, 2013 and SEBI ICDR Regulations, 2018, subject to receipt of necessary approvals including shareholder approval and other regulatory/statutory approvals.

2. Delegation of Authority:

The Board authorized Mr. Tejas Hathi, Managing Director (DIN: 03151221), to undertake specific activities related to the preferential allotment:

  • Identify, evaluate, conduct due diligence on, and negotiate with prospective investors/allottees
  • Finalize names, categories, and details of proposed allottees in accordance with SEBI ICDR Regulations
  • Collect requisite information, declarations, and documents from proposed allottees
  • Place a comprehensive report before the Board for final approval

3. Important Clarifications:

  • The resolutions are enabling/in-principle approvals establishing maximum ceilings for fund raising
  • Specific details including issue price, number of securities, identity of allottees, record date, and other material particulars have not been finalized
  • These details will be approved at a subsequent Board meeting followed by comprehensive disclosure under Regulation 30 of SEBI LODR Regulations
  • Shareholder approval by Special Resolution at EGM/AGM and other regulatory approvals will be obtained before implementation

The information has been simultaneously hosted on the company website at www.aptuspharma.com.